Fig. 1.
Fig. 1. Human Lin− PBMCs. / Analysis of human Lin− PBMC preparations obtained using a mAb mix containing either CD16 (A-E and K-O) or CD56 mAb (F-J and P-T). Lin− cells were stained with FITC-SAM (to detect residual Lin+ cells) and HLA-DR in conjunction with one of a panel of lineage mAbs. Flow cytometry profiles of (A) CD16-depleted or (F) CD56-depleted residual lineage-labeling intensity shows 3 peaks: R1, R2, and R3. The Lin−HLA-DR+ cells (B,G) were analyzed further for CD20 (C,H), CD7 (D,I), CD64 (E,J), CD14 (K,P), CD16 (L,Q), CD56 (M,R), CD11c (N,S), and CD33 (O,T).

Human Lin PBMCs.

Analysis of human Lin PBMC preparations obtained using a mAb mix containing either CD16 (A-E and K-O) or CD56 mAb (F-J and P-T). Lin cells were stained with FITC-SAM (to detect residual Lin+ cells) and HLA-DR in conjunction with one of a panel of lineage mAbs. Flow cytometry profiles of (A) CD16-depleted or (F) CD56-depleted residual lineage-labeling intensity shows 3 peaks: R1, R2, and R3. The LinHLA-DR+ cells (B,G) were analyzed further for CD20 (C,H), CD7 (D,I), CD64 (E,J), CD14 (K,P), CD16 (L,Q), CD56 (M,R), CD11c (N,S), and CD33 (O,T).

Close Modal

or Create an Account

Close Modal
Close Modal